MAIA Biotechnology, Inc. (NYSE American: MAIA), a pioneering company focused on developing immunotherapies targeting telomeres for cancer treatment, has confirmed its participation in the prestigious BIO International Convention scheduled from June 3 to June 6, 2024, in San Diego, California. Recognized as the premier gathering for the biotechnology industry, this event attracts over 20,000 global leaders in the biotech sector.
Dr. Vlad Vitoc, Chairman and CEO of MAIA, will present the latest insights from the company’s Phase 2 THIO-101 clinical trial during the convention. This trial assesses the efficacy of THIO, a novel telomere-targeting anticancer agent, when combined with the immune checkpoint inhibitor cemiplimab (Libtayo®) for advanced non-small cell lung cancer (NSCLC). THIO works by inducing direct telomeric DNA damage and eliciting cancer-specific immune responses. Notably, THIO-101 is poised to become the first completed clinical study of its kind in cancer drug development.
Dr. Vitoc’s presentation is scheduled for Wednesday, June 5, at 11:30 a.m. PDT in Company Presentation Theater 1 at the San Diego Convention Center’s Hall A. Additionally, Dr. Vitoc and his team will be available for discussions with pharmaceutical executives, researchers, and other attendees throughout the duration of the convention. Meetings can be scheduled through the BIO One-on-One Partnering™ platform on the convention website.
BIO (Biotechnology Innovation Organization) is the leading advocacy association representing biotechnology companies, academic and research institutions, state biotechnology centers, and related organizations in the United States and over 30 other countries.
THIO (6-thio-dG or 6-thio-2’-deoxyguanosine) is a first-in-class investigational telomere-targeting agent currently undergoing clinical development for Non-Small Cell Lung Cancer (NSCLC). Telomeres, along with the enzyme telomerase, are crucial for cancer cell survival and resistance to existing therapies. THIO induces telomerase-dependent telomeric DNA modification, triggering DNA damage responses and selective cancer cell death. The compound also activates both innate (cGAS/STING) and adaptive (T-cell) immune responses, leading to tumor regression and immune memory in preclinical models.
THIO-101 is a multicenter, open-label, dose-finding Phase 2 clinical trial evaluating THIO’s anti-tumor activity when combined with PD-(L)1 inhibition. The trial aims to demonstrate the safety, tolerability, and clinical efficacy of THIO as a priming immune activator in patients with advanced NSCLC who have not responded to previous checkpoint inhibitor treatment regimens. The primary endpoint of the trial is Overall Response Rate (ORR). Initial results indicate favorable tolerability in heavily pre-treated patients. More information on this Phase II trial is available on ClinicalTrials.gov using the identifier NCT05208944.”
